Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
108.65
-18.93 (-14.84%)
At close: May 12, 2026, 4:00 PM EDT
104.99
-3.66 (-3.37%)
Pre-market: May 13, 2026, 6:11 AM EDT
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
| Name | Position |
|---|---|
| Dr. Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer |
| Dr. Carlos Bais Ph.D. | EVP & Chief Scientific Officer |
| Dr. Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer |
| Mr. David J. Matly M.B.A. | President |
| Mr. Mark Paul Lappe | Founder, CEO & Chairman |
| Ms. Bonne Adams M.B.A. | Vice President of Operations |
| Ms. Kate Burke CPA, M.B.A. | Vice President of Accounting |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer |
| Ms. Leah Pollema J.D. | VP, General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | inhibrx-20260511.htm |
| 2026-04-23 | DEFA14A | inbx2026additionalproxymat.htm |
| 2026-04-21 | 8-K | inhibrx-20260421.htm |
| 2026-03-19 | 8-K | inhibrx-20260319.htm |
| 2026-02-23 | 8-K | inhibrx-20260223.htm |
| 2025-12-16 | 8-K | inhibrx-20251216.htm |
| 2025-11-14 | 8-K | inhibrx-20251114.htm |
| 2025-10-23 | 8-K | inhibrx-20251023.htm |
| 2025-08-13 | 8-K | inhibrx-20250813.htm |
| 2025-06-02 | POS AM | inbx-posam3filing06022025.htm |